The upregulation of FAK in many carcinomas has led to the development of FAK inhibitors,61,62 and their benefits in breast cancer preclinical models have been demonstrated.63,64,65 Increasing evidence suggests a benefit of combining FAK-kinase inhibitors with chemotherapy in other types of cancer.66,67,68,69 Ongoing and future clinical trials will examine the value of FAK-kinase inhibitor treatment with chemotherapy in breast cancer progression and patient survival. The gene discussed is PTK2; the disease is cancer.